RHHBY - Diving Into Dicerna Pharmaceuticals

• Dicerna Pharmaceuticals’ lead RNAi candidate (nedosiran) is scheduled to read out top-line data from its pivotal trial in mid-2021, with an NDA filing anticipated shortly thereafter.
• The company’s GalXC development platform has attracted five collaborations and more than $500 million in milestone payments to date.
• The company also is collaborating with former bitter rival Alnylam to cross promote their primary hyperoxaluria and alpha-1 liver disease therapies.
• With a platform that produces potentially curative remedies and more than 20 preclinical and discovery programs with its collaborators, Dicerna merited further investigation.

For further details see: